Literature DB >> 18594271

The accelerator hypothesis and increasing incidence of type 1 diabetes.

Spiros Fourlanos1, Leonard C Harrison, Peter G Colman.   

Abstract

PURPOSE OF REVIEW: To summarize the relevance of the 'accelerator hypothesis' to type 1 diabetes pathogenesis and examine if recent evidence supports the hypothesis. The 'accelerator hypothesis' proposes 'three processes in type 1 diabetes which variably accelerate the loss of beta cells through apoptosis: constitution, insulin resistance and autoimmunity'. RECENT
FINDINGS: Insulin resistance is an independent risk factor for progression to clinical type 1 diabetes in people with islet autoimmunity. Higher bodyweight is also associated with type 1 diabetes development although no longitudinal studies have simultaneously assessed bodyweight and insulin resistance in preclinical diabetes. Currently, there is no evidence for the view that accelerated beta-cell apoptosis is due to insulin resistance in the pathogenesis of type 1 diabetes.
SUMMARY: Insulin resistance accelerates development of type 1 diabetes in people with islet autoimmunity and insulin deficiency. The increasingly 'obesogenic' environment which promotes insulin resistance could account for the rising incidence of type 1 diabetes.

Entities:  

Mesh:

Year:  2008        PMID: 18594271     DOI: 10.1097/MED.0b013e3283073a5a

Source DB:  PubMed          Journal:  Curr Opin Endocrinol Diabetes Obes        ISSN: 1752-296X            Impact factor:   3.243


  29 in total

Review 1.  Blockade of interleukin 1 in type 1 diabetes mellitus.

Authors:  Thomas Mandrup-Poulsen; Linda Pickersgill; Marc Yves Donath
Journal:  Nat Rev Endocrinol       Date:  2010-03       Impact factor: 43.330

2.  Lower prediagnostic serum 25-hydroxyvitamin D concentration is associated with higher risk of insulin-requiring diabetes: a nested case-control study.

Authors:  E D Gorham; C F Garland; A A Burgi; S B Mohr; K Zeng; H Hofflich; J J Kim; C Ricordi
Journal:  Diabetologia       Date:  2012-09-07       Impact factor: 10.122

Review 3.  The pathogenesis and natural history of type 1 diabetes.

Authors:  Mark A Atkinson
Journal:  Cold Spring Harb Perspect Med       Date:  2012-11-01       Impact factor: 6.915

4.  Oral Corticosterone Administration Reduces Insulitis but Promotes Insulin Resistance and Hyperglycemia in Male Nonobese Diabetic Mice.

Authors:  Susan J Burke; Heidi M Batdorf; Adrianna E Eder; Michael D Karlstad; David H Burk; Robert C Noland; Z Elizabeth Floyd; J Jason Collier
Journal:  Am J Pathol       Date:  2017-01-04       Impact factor: 4.307

5.  Metabolic pressure and the breach of immunological self-tolerance.

Authors:  Veronica De Rosa; Antonio La Cava; Giuseppe Matarese
Journal:  Nat Immunol       Date:  2017-10-18       Impact factor: 25.606

Review 6.  Connecting type 1 and type 2 diabetes through innate immunity.

Authors:  Justin I Odegaard; Ajay Chawla
Journal:  Cold Spring Harb Perspect Med       Date:  2012-03       Impact factor: 6.915

7.  Inflammatory markers are increased in youth with type 1 diabetes: the SEARCH Case-Control study.

Authors:  Janet K Snell-Bergeon; Nancy A West; Elizabeth J Mayer-Davis; Angela D Liese; Santica M Marcovina; Ralph B D'Agostino; Richard F Hamman; Dana Dabelea
Journal:  J Clin Endocrinol Metab       Date:  2010-04-06       Impact factor: 5.958

8.  Banting Lecture 2009: An unfinished journey: molecular pathogenesis to prevention of type 1A diabetes.

Authors:  George S Eisenbarth
Journal:  Diabetes       Date:  2010-04       Impact factor: 9.461

9.  Increased IFN-α-producing plasmacytoid dendritic cells (pDCs) in human Th1-mediated type 1 diabetes: pDCs augment Th1 responses through IFN-α production.

Authors:  Chang-Qing Xia; Ruihua Peng; Anna V Chernatynskaya; Lihui Yuan; Carolyn Carter; John Valentine; Eric Sobel; Mark A Atkinson; Michael J Clare-Salzler
Journal:  J Immunol       Date:  2014-06-27       Impact factor: 5.422

10.  Incidence of insulin-requiring diabetes in the US military.

Authors:  E D Gorham; E Barrett-Connor; R M Highfill-McRoy; S B Mohr; C F Garland; F C Garland; C Ricordi
Journal:  Diabetologia       Date:  2009-07-24       Impact factor: 10.122

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.